- Yale Physicians Building800 Howard AvenueNew Haven, CT 06519
Aaron Lazorwitz, MD, PhD
Biography
Aaron Lazorwitz, MD, PhD, is an obstetrician and gynecologist who subspecializes in complex family planning. He provides comprehensive reproductive health care, including complicated abortion procedures up to 24 weeks gestational age and complex contraceptive procedures such as difficult intrauterine device (IUD) and implant insertions and removals.
He removes contraceptive implants that are deep or non-palpable (due to migration or improper insertion) in a clinical setting, using self-directed ultrasound guidance. He also provides permanent contraception for those who want it. “Too many patients face barriers and uninformed physicians who will deny them a female sterilization procedure for the wrong reasons,” Dr. Lazorwitz says. “I am happy to provide this service to patients in a nonjudgmental and patient-focused manner.”
Dr. Lazorwitz became a complex family planning subspecialist to help fill gaps he noticed during his training, when he realized patients seeking certain kinds of care often faced stigma. “I saw firsthand the poor outcomes that patients faced when denied the reproductive care they needed,” he says. “I became devoted to providing that care, including abortion care, and ensuring that my patients would not face the same obstacles. My greatest reward is making sure that patients can control their own reproductive autonomy and plan the families they want when they want it.”
An assistant professor at Yale School of Medicine, Dr. Lazorwitz devotes about half of his time to research with a specific focus on the pharmacogenomics of contraception. “I am trying to elucidate how individual genetic differences can help explain why patients have such widely variable experiences with the same contraceptive methods,” he says. “For too long, we have taken a one-method-fits-all approach to contraception and have no current means to personalize the contraceptive counseling process.” He hopes to use genetic research to improve this process by using each patient’s individual genetics to better counsel them on the potential side effects and efficacy of various contraceptive methods.
Titles
- Associate Professor of Obstetrics, Gynecology & Reproductive Sciences
- Associate Program Director for Complex Family Planning Fellowship, Obstetrics, Gynecology & Reproductive Sciences
Education & Training
- PhDUniversity of Colorado Anschutz Medical Campus, Clinical Science (2023)
- FellowshipUniversity of Colorado Anschutz Medical Campus (2018)
- MScUniversity of Colorado Anschutz Medical Campus, Clinical Science (2018)
- ResidencyUniversity of Colorado Anschutz Medical Campus (2016)
- MDUT Southwestern Medical Campus, Medicine (2012)
- BAJohns Hopkins University, Psychology (2008)
Additional Information
- University of Colorado Health Hospital Excellence in Care Award: UCH Medical Staff Association (2023)
- NICHD Loan Repayment Program for Contraception and Infertility Research Extramural Award: NICHD (2020), (2022)
- Medical Student Teaching Award: University of Colorado Anschutz Medical Campus (2018)
- Ryan Program Resident Award for Excellence in Family Planning: University of Colorado OB/GYN Department (2015)
- Medical Student Teaching Award: University of Colorado Anschutz Medical Campus (2015)
- American Board of Obstetricians & Gynecologists CFP Job Task Analysis (2024): Complex Family Planning Subject Matter Expert for Second Phase
- Medical Students For Choice: Yale Medical School Chapter (2024 - Present): Faculty advisor
- 3 Daughters (2024 - Present): Consultant
- Society of Family Planning Research Fund: Side effects matter: Centering people's experiences with contraceptive side effects (2023): Grant Reviewer
- American Board of Obstetricians & Gynecologists CFP Job Task Analysis (2023): Complex Family Planning Subject Matter Expert for First Phase
- Division of Reproductive Health at the Centers for Disease Control and Prevention (2023): Member of Guideline Development Meeting
- University of Colorado Colorado Center for Personalized Medicine (2023 - Present): Affiliate
- Society of Family Planning Annual Clinical Meeting (2023 - Present): Abstract Reviewer
- Society of Reproductive Investigation Annual Scientific Meeting (2022 - 2024): Abstract Reviewer
- Comprehensive Women's Health Center CLIA Laboratory (2022 - 2023): Director
- Zaman A, Lazorwitz A, Strawderman M, Liu H, Tydings S, Groth S, Catenacci V, Thomas E. A Pilot and Feasibility Study of Combined Oral Contraceptive Pills and Metabolic Outcomes in Premenopausal Women with Overweight or Obesity. Women 2026, 6: 19. DOI: 10.3390/women6010019.
- Cao A, Zita S, Kim W, Stevenson E, Goodman L, Wang M, Hugh J, Guidry J, Mirhossaini R, Lazorwitz A, Stephen S, Newman S. The effect of levonorgestrel‐releasing intrauterine devices on acne vulgaris: A prospective cohort study. International Journal Of Gynecology & Obstetrics 2026 PMID: 41714837, DOI: 10.1002/ijgo.70912.
- Marcy D, Sturm K, Skorupa T, Maretz C, Bedoya G, Lazorwitz A, Kwag J, Demoruelle M, Zell J. Reproductive Health Counseling in Rheumatology: Gaps, Barriers, and Patient Impact. Arthritis Care & Research 2026 PMID: 41664239, DOI: 10.1002/acr.80014.
- Zaman A, Lazorwitz A, Wierman M. Contraceptive Selection for the Endocrine Patient: What an Endocrinologist Should Know. Endocrine Reviews 2025, 46: 736-759. PMID: 40519043, DOI: 10.1210/endrev/bnaf016.
- Jimenez A, Toghramadjian I, Okafor C, Hanin A, Zhou X, Dorotan M, Nuthalapati P, Sakya S, Hirsch L, Altalib H, Lazorwitz A, Herlopian A. Cenobamate and pregnancy: A-single level 4 epilepsy center experience. Epilepsy & Behavior 2025, 169: 110440. PMID: 40318387, DOI: 10.1016/j.yebeh.2025.110440.
- Lazorwitz A, Aquilante C, Shortt J, Gignoux C, Teal S, Sheeder J. Pharmacogenomics of the Etonogestrel Contraceptive Implant. O&G Open 2025, 2: e066-e066. PMID: 41000562, PMCID: PMC12456479, DOI: 10.1097/og9.0000000000000066.
- Friedman J, Sheeder J, Polotsky A, Lazorwitz A. Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic. Obstetrical & Gynecological Survey 2024, 79: 643-644. DOI: 10.1097/01.ogx.0001095056.57063.30.
- Gross D, Wang C, Page S, Sitruk-Ware R, Creinin M, Anderson R, Edelman A, Turok D, Kinuthia J, Vinay J, Barnhart K, Danielsson K, Mhlanga F, Fitzgerald C, Meriggiola C, Archer D, Lazorwitz A, Amory J, Swerdloff R, Bremner W, Lee M, Kroopnick J, Blithe D. OR24-01 Time to Sperm Suppression With Daily Transdermal Use of Nestorone and Testosterone Combination Gel for Male Contraception Is Faster Than Expected. Journal Of The Endocrine Society 2024, 8: bvae163.2435. PMCID: PMC12047133, DOI: 10.1210/jendso/bvae163.2435.
- Lazorwitz A, Sheeder J, Teal S. The influence of lifestyle factors on serum etonogestrel concentrations among contraceptive implant users. Contraception 2024, 140: 110539. PMID: 39002624, PMCID: PMC11588555, DOI: 10.1016/j.contraception.2024.110539.
- Kendall P, Bresnitz W, Huang J, Sheeder J, Lazorwitz A. A retrospective analysis of factors associated with deep contraceptive implant removals compared to superficial removals. Contraception 2024, 137: 110486. PMID: 38754757, DOI: 10.1016/j.contraception.2024.110486.
- Masten M, Sheeder J, Lazorwitz A. Substance Use and Anxiety About Pain Among Patients Seeking Abortion Services. Cureus 2024, 16: e57034. PMID: 38681459, PMCID: PMC11047799, DOI: 10.7759/cureus.57034.
- Clure C, Sheeder J, Lazorwitz A. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant. Contraception 2024, 135: 110442. PMID: 38552822, DOI: 10.1016/j.contraception.2024.110442.
- Kendall P, Lazorwitz A. Letter to the Editor in Response to ‘Population-based cohort study of oral contraceptive use and risk of depression’. Epidemiology And Psychiatric Sciences 2024, 33: e4. PMID: 38299323, PMCID: PMC10894698, DOI: 10.1017/s2045796024000039.
- Friedman J, Sheeder J, Polotsky A, Lazorwitz A. Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic. Journal Of Pediatric And Adolescent Gynecology 2023, 37: 323-329. PMID: 38061680, DOI: 10.1016/j.jpag.2023.11.012.
- Drake E, Larrea N, Wolverton E, Tibbits B, Lazorwitz A, Schultz C. Feasibility and Utility of Posttraumatic Stress Disorder Screening Among Postpartum Patients at an Urban Safety-Net Institution. Obstetrics And Gynecology 2023, 142: 1455-1458. PMID: 37884025, DOI: 10.1097/aog.0000000000005422.
- Diamond B, Sheeder J, Lazorwitz A. An exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users. Contraception 2023, 129: 110298. PMID: 37802462, PMCID: PMC10842501, DOI: 10.1016/j.contraception.2023.110298.
- Lazorwitz A, Sheeder J. Validation of 24-hour trough concentration as a proxy for intensive pharmacokinetic measurements for a combined oral contraceptive pill containing desogestrel. Contraception 2023, 126: 110093. PMID: 37331464, PMCID: PMC10528283, DOI: 10.1016/j.contraception.2023.110093.
- Lazorwitz A, Sheeder J, Teal S. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study. Contraception 2023, 123: 110035. PMID: 36997081, PMCID: PMC10461170, DOI: 10.1016/j.contraception.2023.110035.
- Friedman J, Sheeder J, Lazorwitz A, Polotsky A. Herbal supplement use among reproductive-aged women in an academic infertility practice. F&S Reports 2022, 4: 104-111. PMID: 36959959, PMCID: PMC10028423, DOI: 10.1016/j.xfre.2022.12.001.
- Lazorwitz A, Teal S, Sheeder J. P079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer. Contraception 2022, 116: 92. DOI: 10.1016/j.contraception.2022.09.103.
- Clure C, Sheeder J, Lazorwitz A. P077Pilot study on a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant. Contraception 2022, 116: 91. DOI: 10.1016/j.contraception.2022.09.101.
- Masten M, Larrea N, Schultz C, Lazorwitz A. Short-notice cancellations of laparoscopic permanent contraception. Contraception 2022, 114: 49-53. PMID: 35545130, DOI: 10.1016/j.contraception.2022.04.013.
- Friedman J, Sheeder J, Lazorwitz A. Herbal Supplement Use Among Adolescent Women in a Family Planning Clinic. Journal Of Pediatric And Adolescent Gynecology 2022, 35: 238. DOI: 10.1016/j.jpag.2022.01.120.
- Lazorwitz A, Pena M, Sheeder J, Teal S. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2022, 139: 579-587. PMID: 35594123, PMCID: PMC9140306, DOI: 10.1097/aog.0000000000004697.
- Wilson C, Lazorwitz A, Hyer J, Guiahi M. Concordance of Desired and Administered Postpartum Contraceptives among Emergency and Full Scope Medicaid Patients. Women's Health Issues 2022, 32: 343-351. PMID: 35272884, DOI: 10.1016/j.whi.2022.01.008.
- Novick AM, Johnson RL, Lazorwitz A, Belyavskaya A, Berkowitz L, Norton A, Sammel MD, Epperson CN. Discontinuation of hormonal contraception due to changes in mood and decreases in sexual desire: the role of adverse childhood experiences. The European Journal Of Contraception & Reproductive Health Care 2022, 27: 212-220. PMID: 35133231, PMCID: PMC9133050, DOI: 10.1080/13625187.2022.2030702.
- Lazorwitz A, Sheeder J, Teal S. Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period. Contraception 2021, 108: 65-68. PMID: 34973207, PMCID: PMC9011406, DOI: 10.1016/j.contraception.2021.12.008.
- Peña M, Montford N, Sheeder J, Lazorwitz A. POSTER ABSTRACTS P75 DEMOGRAPHIC DIVERSITY IN CONTRACEPTIVE CLINICAL TRIALS CONDUCTED AT AN ACADEMIC MEDICAL CENTER. Contraception 2021, 104: 469. DOI: 10.1016/j.contraception.2021.07.093.
- Lazorwitz A, Peña M, Sheeder J, Teal S. POSTER ABSTRACTS P58 THE EFFECT OF TOPIRAMATE ON ETONOGESTREL CONCENTRATIONS IN CONTRACEPTIVE IMPLANT USERS. Contraception 2021, 104: 465. DOI: 10.1016/j.contraception.2021.07.076.
- Lazorwitz A, Carrasco E, Cecula P, Sheeder J. INTEREST FOR AN AT-HOME TESTING KIT PROVIDING PERSONALIZED CONTRACEPTIVE RECOMMENDATIONS AMONG REPRODUCTIVE-AGE FEMALES. Fertility And Sterility 2021, 116: e292. DOI: 10.1016/j.fertnstert.2021.07.784.
- Lew J, Sheeder J, Lazorwitz A. Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients. Contraception 2021, 104: 556-560. PMID: 34147509, PMCID: PMC8502202, DOI: 10.1016/j.contraception.2021.06.007.
- Lazorwitz A, Aquilante C, Shortt J, Sheeder J, Teal S, Gignoux C. Applicability of ancestral genotyping in pharmacogenomic research with hormonal contraception. Clinical And Translational Science 2021, 14: 1713-1718. PMID: 33650294, PMCID: PMC8504805, DOI: 10.1111/cts.13014.
- Lazorwitz A, Teal S. Using pharmacologic research to efficiently meet acute contraceptive needs. Fertility And Sterility 2021, 115: 903-904. PMID: 33832748, PMCID: PMC9136044, DOI: 10.1016/j.fertnstert.2021.02.027.
- Lazorwitz A, Sheeder J, Teal S. An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users. The European Journal Of Contraception & Reproductive Health Care 2021, 26: 323-325. PMID: 33596152, PMCID: PMC8496990, DOI: 10.1080/13625187.2021.1887475.
- Lazorwitz A, Dindinger E, Harrison M, Aquilante C, Sheeder J, Teal S. An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users. Contraception 2020, 102: 180-185. PMID: 32407811, PMCID: PMC7483263, DOI: 10.1016/j.contraception.2020.05.002.
- Lazorwitz A, Seale R, Davis A, Guiahi M. A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users. Contraception 2020, 102: 58-60. PMID: 32325076, PMCID: PMC7272275, DOI: 10.1016/j.contraception.2020.04.011.
- Fang N, Guiahi M, Lazorwitz A. Satisfaction with medication abortion and marijuana use: A prospective cohort study. Contraception 2020, 102: 30-33. PMID: 32278684, DOI: 10.1016/j.contraception.2020.03.008.
- Lazorwitz A, Aquilante C, Sheeder J, Teal S. Letter to the Editor in Response to “Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally”. Advances In Therapy 2019, 37: 963-964. PMID: 31875298, PMCID: PMC6995783, DOI: 10.1007/s12325-019-01195-y.
- Lazorwitz A, Dindinger E, Aguirre N, Sheeder J. Pre- and post-operative counseling for women on hormonal contraceptives receiving sugammadex at an academic hospital. Journal Of Anesthesia 2019, 34: 294-297. PMID: 31865457, PMCID: PMC8496978, DOI: 10.1007/s00540-019-02725-2.
- Lazorwitz A, Aquilante C, Dindinger E, Harrison M, Sheeder J, Teal S. Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users. Obstetrics And Gynecology 2019, 134: 807-813. PMID: 31503152, PMCID: PMC6768730, DOI: 10.1097/aog.0000000000003452.
- Lazorwitz A, Dindinger E, Harrison M, Aquilante C, Sheeder J, Teal S. Influence of genetic variants on weight gain among etonogestrel contraceptive implant users. Fertility And Sterility 2019, 112: e9-e10. DOI: 10.1016/j.fertnstert.2019.07.161.
- Lazorwitz A, Aquilante C, Sheeder J, Guiahi M, Teal S. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users. Contraception 2019, 100: 37-41. PMID: 30980827, PMCID: PMC6589369, DOI: 10.1016/j.contraception.2019.03.045.
- Lazorwitz A, Aquilante C, Oreschak K, Sheeder J, Guiahi M, Teal S. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2019, 133: 783-794. PMID: 30870275, PMCID: PMC6448146, DOI: 10.1097/aog.0000000000003189.
- Lazorwitz A, Coleman-Minahan K, Teal S, Guiahi M. Ongoing Etonogestrel Contraceptive Implant Use Throughout Pregnancy. Journal Of Adolescent Health 2018, 63: 363-364. PMID: 30076014, DOI: 10.1016/j.jadohealth.2018.03.021.
- Lazorwitz A, Tocce K. A case series of removal of nickel–titanium sterilization microinserts from the uterine cornua using laparoscopic electrocautery for salpingectomy. Contraception 2017, 96: 96-98. PMID: 28606383, DOI: 10.1016/j.contraception.2017.06.002.
- Lazorwitz A, Davis A, Swartz M, Guiahi M. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users. Contraception 2017, 95: 571-577. PMID: 28288788, DOI: 10.1016/j.contraception.2017.03.004.
- Lazorwitz A, Swartz M, Davis A, Guiahi M. The effect of carbamazepine on etonogestrel concentrations among contraceptive implant users. Contraception 2016, 94: 389. DOI: 10.1016/j.contraception.2016.07.029.
- Lazorwitz A, Sheeder J, Teal S, Guiahi M. Does the expectation or perception of noncontraceptive benefits lead to higher rates of short-acting reversible contraceptive continuation for adolescents and young adult women? Contraception 2015, 91: 380-385. PMID: 25684618, DOI: 10.1016/j.contraception.2015.02.003.
- Lazorwitz A, Sheeder J, Teal S, Guiahi M. Does the expectation or perception of noncontraceptive benefits lead to higher rates of contraceptive continuation for adolescents and young adult women? Contraception 2014, 90: 319. DOI: 10.1016/j.contraception.2014.05.093.
- Lazorwitz A, Guiahi M. Emergency Contraception. Topics In Obstetrics & Gynecology 2014, 34: 1-6. DOI: 10.1097/01.pgo.0000449926.51072.c3.
- Lazorwitz A, Guiahi M. Increasing Use of and Adherence to Long-Acting Reversible Contraceptive Methods in Adolescents and Young Adult Women. Topics In Obstetrics & Gynecology 2014, 34: 1-7. DOI: 10.1097/01.pgo.0000442955.12502.a3.
- Identification of Breast Cancer DNA Methylation Markers Optimized for Fine-Needle Aspiration SamplesBu D, Lewis C, Sarode V, Chen M, Ma X, Lazorwitz A, Rao R, Leitch M, Moldrem A, Andrews V, Gazdar A, Euhus D. Identification of Breast Cancer DNA Methylation Markers Optimized for Fine-Needle Aspiration Samples. Cancer Epidemiology Biomarkers & Prevention 2013, 22: 2212-2221. PMID: 24089458, DOI: 10.1158/1055-9965.epi-13-0208.
- Yale Physicians Building800 Howard AvenueNew Haven, CT 06519
Biography
Aaron Lazorwitz, MD, PhD, is an obstetrician and gynecologist who subspecializes in complex family planning. He provides comprehensive reproductive health care, including complicated abortion procedures up to 24 weeks gestational age and complex contraceptive procedures such as difficult intrauterine device (IUD) and implant insertions and removals.
He removes contraceptive implants that are deep or non-palpable (due to migration or improper insertion) in a clinical setting, using self-directed ultrasound guidance. He also provides permanent contraception for those who want it. “Too many patients face barriers and uninformed physicians who will deny them a female sterilization procedure for the wrong reasons,” Dr. Lazorwitz says. “I am happy to provide this service to patients in a nonjudgmental and patient-focused manner.”
Dr. Lazorwitz became a complex family planning subspecialist to help fill gaps he noticed during his training, when he realized patients seeking certain kinds of care often faced stigma. “I saw firsthand the poor outcomes that patients faced when denied the reproductive care they needed,” he says. “I became devoted to providing that care, including abortion care, and ensuring that my patients would not face the same obstacles. My greatest reward is making sure that patients can control their own reproductive autonomy and plan the families they want when they want it.”
An assistant professor at Yale School of Medicine, Dr. Lazorwitz devotes about half of his time to research with a specific focus on the pharmacogenomics of contraception. “I am trying to elucidate how individual genetic differences can help explain why patients have such widely variable experiences with the same contraceptive methods,” he says. “For too long, we have taken a one-method-fits-all approach to contraception and have no current means to personalize the contraceptive counseling process.” He hopes to use genetic research to improve this process by using each patient’s individual genetics to better counsel them on the potential side effects and efficacy of various contraceptive methods.
Titles
- Associate Professor of Obstetrics, Gynecology & Reproductive Sciences
- Associate Program Director for Complex Family Planning Fellowship, Obstetrics, Gynecology & Reproductive Sciences
Education & Training
- PhDUniversity of Colorado Anschutz Medical Campus, Clinical Science (2023)
- FellowshipUniversity of Colorado Anschutz Medical Campus (2018)
- MScUniversity of Colorado Anschutz Medical Campus, Clinical Science (2018)
- ResidencyUniversity of Colorado Anschutz Medical Campus (2016)
- MDUT Southwestern Medical Campus, Medicine (2012)
- BAJohns Hopkins University, Psychology (2008)
Additional Information
- University of Colorado Health Hospital Excellence in Care Award: UCH Medical Staff Association (2023)
- NICHD Loan Repayment Program for Contraception and Infertility Research Extramural Award: NICHD (2020), (2022)
- Medical Student Teaching Award: University of Colorado Anschutz Medical Campus (2018)
- Ryan Program Resident Award for Excellence in Family Planning: University of Colorado OB/GYN Department (2015)
- Medical Student Teaching Award: University of Colorado Anschutz Medical Campus (2015)
- American Board of Obstetricians & Gynecologists CFP Job Task Analysis (2024): Complex Family Planning Subject Matter Expert for Second Phase
- Medical Students For Choice: Yale Medical School Chapter (2024 - Present): Faculty advisor
- 3 Daughters (2024 - Present): Consultant
- Society of Family Planning Research Fund: Side effects matter: Centering people's experiences with contraceptive side effects (2023): Grant Reviewer
- American Board of Obstetricians & Gynecologists CFP Job Task Analysis (2023): Complex Family Planning Subject Matter Expert for First Phase
- Division of Reproductive Health at the Centers for Disease Control and Prevention (2023): Member of Guideline Development Meeting
- University of Colorado Colorado Center for Personalized Medicine (2023 - Present): Affiliate
- Society of Family Planning Annual Clinical Meeting (2023 - Present): Abstract Reviewer
- Society of Reproductive Investigation Annual Scientific Meeting (2022 - 2024): Abstract Reviewer
- Comprehensive Women's Health Center CLIA Laboratory (2022 - 2023): Director
- Zaman A, Lazorwitz A, Strawderman M, Liu H, Tydings S, Groth S, Catenacci V, Thomas E. A Pilot and Feasibility Study of Combined Oral Contraceptive Pills and Metabolic Outcomes in Premenopausal Women with Overweight or Obesity. Women 2026, 6: 19. DOI: 10.3390/women6010019.
- Cao A, Zita S, Kim W, Stevenson E, Goodman L, Wang M, Hugh J, Guidry J, Mirhossaini R, Lazorwitz A, Stephen S, Newman S. The effect of levonorgestrel‐releasing intrauterine devices on acne vulgaris: A prospective cohort study. International Journal Of Gynecology & Obstetrics 2026 PMID: 41714837, DOI: 10.1002/ijgo.70912.
- Marcy D, Sturm K, Skorupa T, Maretz C, Bedoya G, Lazorwitz A, Kwag J, Demoruelle M, Zell J. Reproductive Health Counseling in Rheumatology: Gaps, Barriers, and Patient Impact. Arthritis Care & Research 2026 PMID: 41664239, DOI: 10.1002/acr.80014.
- Zaman A, Lazorwitz A, Wierman M. Contraceptive Selection for the Endocrine Patient: What an Endocrinologist Should Know. Endocrine Reviews 2025, 46: 736-759. PMID: 40519043, DOI: 10.1210/endrev/bnaf016.
- Jimenez A, Toghramadjian I, Okafor C, Hanin A, Zhou X, Dorotan M, Nuthalapati P, Sakya S, Hirsch L, Altalib H, Lazorwitz A, Herlopian A. Cenobamate and pregnancy: A-single level 4 epilepsy center experience. Epilepsy & Behavior 2025, 169: 110440. PMID: 40318387, DOI: 10.1016/j.yebeh.2025.110440.
- Lazorwitz A, Aquilante C, Shortt J, Gignoux C, Teal S, Sheeder J. Pharmacogenomics of the Etonogestrel Contraceptive Implant. O&G Open 2025, 2: e066-e066. PMID: 41000562, PMCID: PMC12456479, DOI: 10.1097/og9.0000000000000066.
- Friedman J, Sheeder J, Polotsky A, Lazorwitz A. Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic. Obstetrical & Gynecological Survey 2024, 79: 643-644. DOI: 10.1097/01.ogx.0001095056.57063.30.
- Gross D, Wang C, Page S, Sitruk-Ware R, Creinin M, Anderson R, Edelman A, Turok D, Kinuthia J, Vinay J, Barnhart K, Danielsson K, Mhlanga F, Fitzgerald C, Meriggiola C, Archer D, Lazorwitz A, Amory J, Swerdloff R, Bremner W, Lee M, Kroopnick J, Blithe D. OR24-01 Time to Sperm Suppression With Daily Transdermal Use of Nestorone and Testosterone Combination Gel for Male Contraception Is Faster Than Expected. Journal Of The Endocrine Society 2024, 8: bvae163.2435. PMCID: PMC12047133, DOI: 10.1210/jendso/bvae163.2435.
- Lazorwitz A, Sheeder J, Teal S. The influence of lifestyle factors on serum etonogestrel concentrations among contraceptive implant users. Contraception 2024, 140: 110539. PMID: 39002624, PMCID: PMC11588555, DOI: 10.1016/j.contraception.2024.110539.
- Kendall P, Bresnitz W, Huang J, Sheeder J, Lazorwitz A. A retrospective analysis of factors associated with deep contraceptive implant removals compared to superficial removals. Contraception 2024, 137: 110486. PMID: 38754757, DOI: 10.1016/j.contraception.2024.110486.
- Masten M, Sheeder J, Lazorwitz A. Substance Use and Anxiety About Pain Among Patients Seeking Abortion Services. Cureus 2024, 16: e57034. PMID: 38681459, PMCID: PMC11047799, DOI: 10.7759/cureus.57034.
- Clure C, Sheeder J, Lazorwitz A. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant. Contraception 2024, 135: 110442. PMID: 38552822, DOI: 10.1016/j.contraception.2024.110442.
- Kendall P, Lazorwitz A. Letter to the Editor in Response to ‘Population-based cohort study of oral contraceptive use and risk of depression’. Epidemiology And Psychiatric Sciences 2024, 33: e4. PMID: 38299323, PMCID: PMC10894698, DOI: 10.1017/s2045796024000039.
- Friedman J, Sheeder J, Polotsky A, Lazorwitz A. Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic. Journal Of Pediatric And Adolescent Gynecology 2023, 37: 323-329. PMID: 38061680, DOI: 10.1016/j.jpag.2023.11.012.
- Drake E, Larrea N, Wolverton E, Tibbits B, Lazorwitz A, Schultz C. Feasibility and Utility of Posttraumatic Stress Disorder Screening Among Postpartum Patients at an Urban Safety-Net Institution. Obstetrics And Gynecology 2023, 142: 1455-1458. PMID: 37884025, DOI: 10.1097/aog.0000000000005422.
- Diamond B, Sheeder J, Lazorwitz A. An exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users. Contraception 2023, 129: 110298. PMID: 37802462, PMCID: PMC10842501, DOI: 10.1016/j.contraception.2023.110298.
- Lazorwitz A, Sheeder J. Validation of 24-hour trough concentration as a proxy for intensive pharmacokinetic measurements for a combined oral contraceptive pill containing desogestrel. Contraception 2023, 126: 110093. PMID: 37331464, PMCID: PMC10528283, DOI: 10.1016/j.contraception.2023.110093.
- Lazorwitz A, Sheeder J, Teal S. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study. Contraception 2023, 123: 110035. PMID: 36997081, PMCID: PMC10461170, DOI: 10.1016/j.contraception.2023.110035.
- Friedman J, Sheeder J, Lazorwitz A, Polotsky A. Herbal supplement use among reproductive-aged women in an academic infertility practice. F&S Reports 2022, 4: 104-111. PMID: 36959959, PMCID: PMC10028423, DOI: 10.1016/j.xfre.2022.12.001.
- Lazorwitz A, Teal S, Sheeder J. P079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer. Contraception 2022, 116: 92. DOI: 10.1016/j.contraception.2022.09.103.
- Clure C, Sheeder J, Lazorwitz A. P077Pilot study on a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant. Contraception 2022, 116: 91. DOI: 10.1016/j.contraception.2022.09.101.
- Masten M, Larrea N, Schultz C, Lazorwitz A. Short-notice cancellations of laparoscopic permanent contraception. Contraception 2022, 114: 49-53. PMID: 35545130, DOI: 10.1016/j.contraception.2022.04.013.
- Friedman J, Sheeder J, Lazorwitz A. Herbal Supplement Use Among Adolescent Women in a Family Planning Clinic. Journal Of Pediatric And Adolescent Gynecology 2022, 35: 238. DOI: 10.1016/j.jpag.2022.01.120.
- Lazorwitz A, Pena M, Sheeder J, Teal S. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2022, 139: 579-587. PMID: 35594123, PMCID: PMC9140306, DOI: 10.1097/aog.0000000000004697.
- Wilson C, Lazorwitz A, Hyer J, Guiahi M. Concordance of Desired and Administered Postpartum Contraceptives among Emergency and Full Scope Medicaid Patients. Women's Health Issues 2022, 32: 343-351. PMID: 35272884, DOI: 10.1016/j.whi.2022.01.008.
- Novick AM, Johnson RL, Lazorwitz A, Belyavskaya A, Berkowitz L, Norton A, Sammel MD, Epperson CN. Discontinuation of hormonal contraception due to changes in mood and decreases in sexual desire: the role of adverse childhood experiences. The European Journal Of Contraception & Reproductive Health Care 2022, 27: 212-220. PMID: 35133231, PMCID: PMC9133050, DOI: 10.1080/13625187.2022.2030702.
- Lazorwitz A, Sheeder J, Teal S. Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period. Contraception 2021, 108: 65-68. PMID: 34973207, PMCID: PMC9011406, DOI: 10.1016/j.contraception.2021.12.008.
- Peña M, Montford N, Sheeder J, Lazorwitz A. POSTER ABSTRACTS P75 DEMOGRAPHIC DIVERSITY IN CONTRACEPTIVE CLINICAL TRIALS CONDUCTED AT AN ACADEMIC MEDICAL CENTER. Contraception 2021, 104: 469. DOI: 10.1016/j.contraception.2021.07.093.
- Lazorwitz A, Peña M, Sheeder J, Teal S. POSTER ABSTRACTS P58 THE EFFECT OF TOPIRAMATE ON ETONOGESTREL CONCENTRATIONS IN CONTRACEPTIVE IMPLANT USERS. Contraception 2021, 104: 465. DOI: 10.1016/j.contraception.2021.07.076.
- Lazorwitz A, Carrasco E, Cecula P, Sheeder J. INTEREST FOR AN AT-HOME TESTING KIT PROVIDING PERSONALIZED CONTRACEPTIVE RECOMMENDATIONS AMONG REPRODUCTIVE-AGE FEMALES. Fertility And Sterility 2021, 116: e292. DOI: 10.1016/j.fertnstert.2021.07.784.
- Lew J, Sheeder J, Lazorwitz A. Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients. Contraception 2021, 104: 556-560. PMID: 34147509, PMCID: PMC8502202, DOI: 10.1016/j.contraception.2021.06.007.
- Lazorwitz A, Aquilante C, Shortt J, Sheeder J, Teal S, Gignoux C. Applicability of ancestral genotyping in pharmacogenomic research with hormonal contraception. Clinical And Translational Science 2021, 14: 1713-1718. PMID: 33650294, PMCID: PMC8504805, DOI: 10.1111/cts.13014.
- Lazorwitz A, Teal S. Using pharmacologic research to efficiently meet acute contraceptive needs. Fertility And Sterility 2021, 115: 903-904. PMID: 33832748, PMCID: PMC9136044, DOI: 10.1016/j.fertnstert.2021.02.027.
- Lazorwitz A, Sheeder J, Teal S. An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users. The European Journal Of Contraception & Reproductive Health Care 2021, 26: 323-325. PMID: 33596152, PMCID: PMC8496990, DOI: 10.1080/13625187.2021.1887475.
- Lazorwitz A, Dindinger E, Harrison M, Aquilante C, Sheeder J, Teal S. An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users. Contraception 2020, 102: 180-185. PMID: 32407811, PMCID: PMC7483263, DOI: 10.1016/j.contraception.2020.05.002.
- Lazorwitz A, Seale R, Davis A, Guiahi M. A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users. Contraception 2020, 102: 58-60. PMID: 32325076, PMCID: PMC7272275, DOI: 10.1016/j.contraception.2020.04.011.
- Fang N, Guiahi M, Lazorwitz A. Satisfaction with medication abortion and marijuana use: A prospective cohort study. Contraception 2020, 102: 30-33. PMID: 32278684, DOI: 10.1016/j.contraception.2020.03.008.
- Lazorwitz A, Aquilante C, Sheeder J, Teal S. Letter to the Editor in Response to “Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally”. Advances In Therapy 2019, 37: 963-964. PMID: 31875298, PMCID: PMC6995783, DOI: 10.1007/s12325-019-01195-y.
- Lazorwitz A, Dindinger E, Aguirre N, Sheeder J. Pre- and post-operative counseling for women on hormonal contraceptives receiving sugammadex at an academic hospital. Journal Of Anesthesia 2019, 34: 294-297. PMID: 31865457, PMCID: PMC8496978, DOI: 10.1007/s00540-019-02725-2.
- Lazorwitz A, Aquilante C, Dindinger E, Harrison M, Sheeder J, Teal S. Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users. Obstetrics And Gynecology 2019, 134: 807-813. PMID: 31503152, PMCID: PMC6768730, DOI: 10.1097/aog.0000000000003452.
- Lazorwitz A, Dindinger E, Harrison M, Aquilante C, Sheeder J, Teal S. Influence of genetic variants on weight gain among etonogestrel contraceptive implant users. Fertility And Sterility 2019, 112: e9-e10. DOI: 10.1016/j.fertnstert.2019.07.161.
- Lazorwitz A, Aquilante C, Sheeder J, Guiahi M, Teal S. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users. Contraception 2019, 100: 37-41. PMID: 30980827, PMCID: PMC6589369, DOI: 10.1016/j.contraception.2019.03.045.
- Lazorwitz A, Aquilante C, Oreschak K, Sheeder J, Guiahi M, Teal S. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2019, 133: 783-794. PMID: 30870275, PMCID: PMC6448146, DOI: 10.1097/aog.0000000000003189.
- Lazorwitz A, Coleman-Minahan K, Teal S, Guiahi M. Ongoing Etonogestrel Contraceptive Implant Use Throughout Pregnancy. Journal Of Adolescent Health 2018, 63: 363-364. PMID: 30076014, DOI: 10.1016/j.jadohealth.2018.03.021.
- Lazorwitz A, Tocce K. A case series of removal of nickel–titanium sterilization microinserts from the uterine cornua using laparoscopic electrocautery for salpingectomy. Contraception 2017, 96: 96-98. PMID: 28606383, DOI: 10.1016/j.contraception.2017.06.002.
- Lazorwitz A, Davis A, Swartz M, Guiahi M. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users. Contraception 2017, 95: 571-577. PMID: 28288788, DOI: 10.1016/j.contraception.2017.03.004.
- Lazorwitz A, Swartz M, Davis A, Guiahi M. The effect of carbamazepine on etonogestrel concentrations among contraceptive implant users. Contraception 2016, 94: 389. DOI: 10.1016/j.contraception.2016.07.029.
- Lazorwitz A, Sheeder J, Teal S, Guiahi M. Does the expectation or perception of noncontraceptive benefits lead to higher rates of short-acting reversible contraceptive continuation for adolescents and young adult women? Contraception 2015, 91: 380-385. PMID: 25684618, DOI: 10.1016/j.contraception.2015.02.003.
- Lazorwitz A, Sheeder J, Teal S, Guiahi M. Does the expectation or perception of noncontraceptive benefits lead to higher rates of contraceptive continuation for adolescents and young adult women? Contraception 2014, 90: 319. DOI: 10.1016/j.contraception.2014.05.093.
- Lazorwitz A, Guiahi M. Emergency Contraception. Topics In Obstetrics & Gynecology 2014, 34: 1-6. DOI: 10.1097/01.pgo.0000449926.51072.c3.
- Lazorwitz A, Guiahi M. Increasing Use of and Adherence to Long-Acting Reversible Contraceptive Methods in Adolescents and Young Adult Women. Topics In Obstetrics & Gynecology 2014, 34: 1-7. DOI: 10.1097/01.pgo.0000442955.12502.a3.
- Identification of Breast Cancer DNA Methylation Markers Optimized for Fine-Needle Aspiration SamplesBu D, Lewis C, Sarode V, Chen M, Ma X, Lazorwitz A, Rao R, Leitch M, Moldrem A, Andrews V, Gazdar A, Euhus D. Identification of Breast Cancer DNA Methylation Markers Optimized for Fine-Needle Aspiration Samples. Cancer Epidemiology Biomarkers & Prevention 2013, 22: 2212-2221. PMID: 24089458, DOI: 10.1158/1055-9965.epi-13-0208.
- Yale Physicians Building800 Howard AvenueNew Haven, CT 06519
- Yale Physicians Building800 Howard AvenueNew Haven, CT 06519